Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: ICU Medical develops, manufactures, and markets disposable medical devices, primarily vascular therapy connection systems (e.g., CLAVE), custom I.V. systems, and critical care devices. The company operates principally in one segment and relies heavily on a strategic relationship with Hospira, Inc., which accounted for approximately 68% of total revenue in the first nine months of 2008.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended 9/30/08 | Nine Months Ended 9/30/08 | Nine Months Ended 9/30/07 |
|---|---|---|---|
| Total Revenue | $54,735 | $147,981 | $142,591 |
| Gross Profit | $24,947 | $63,522 | $59,220 |
| Gross Margin | 46% | 43% | 42% |
| Net Income | $7,645 | $15,315 | $17,066 |
| Diluted EPS | $0.52 | $1.06 | $1.10 |
| Operating Cash Flow (9mo) | $21,334 | ||
| Cash & Equivalents (9/30/08) | $61,575 | ||
| Marketable Securities (9/30/08) | $55,820 | ||
| Total Current Liabilities | $22,302 |
Note: The company reported no long-term debt on the balance sheet as of September 30, 2008.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 22% year-over-year for the quarter ($54.7M vs. $44.9M) and 4% for the nine-month period ($148.0M vs. $142.6M). Growth was driven by custom products (up 36% in Q3) and CLAVE products (up 15% in Q3), partially offset by a decline in critical care sales due to lower pricing and volume under the Manufacturing Commercialization and Development Agreement (MCDA) with Hospira.
- Profitability: Net income for the quarter rose 62% to $7.6M, driven by higher gross margins (46% vs. 43%) and reduced R&D expenses ($0.9M vs. $2.2M). However, nine-month net income declined 10% to $15.3M, largely due to a one-time $4.8M legal fee charge recorded in Q2 2007 related to patent litigation.
- Liquidity: Cash and cash equivalents surged from $7.9M at year-end 2007 to $61.6M at September 30, 2008. This increase was fueled by strong operating cash flow ($21.3M) and net proceeds from investing activities ($21.9M), primarily from the sale of marketable securities.
- Expense Management: SG&A expenses increased as a percentage of revenue (27% for 9 months vs. 25% prior year) due to higher compensation and marketing costs. R&D expenses decreased significantly as the company focused on core projects.
Guidance, Outlook, and Risks
- Guidance: Management estimates full-year 2008 gross margin will approximate 43%. SG&A is expected to be 26-27% of revenue, and R&D approximately 3%. The effective tax rate is projected to be 31-32% for the first nine months, potentially dropping to 22-24% for the full year due to discrete tax benefits (R&D credits) expected in Q4.
- Outlook: The company expects continued growth in custom products and CLAVE sales in the U.S., though critical care sales may continue to decline. International growth is anticipated but remains modest. Plans to build a manufacturing facility in China have been put on hold.
- Liquidity Risk (Auction Rate Securities): Approximately $23.6 million of marketable securities are classified as Level 3 assets due to failed auctions in the auction rate securities market since February 2008. While the company does not expect credit losses, liquidity is impaired, and there is no assurance these securities can be sold at par or without loss.
- Customer Concentration: Hospira, Inc. remains a dominant customer, representing 68% of revenue for the nine months ended September 30, 2008. An adverse change in this relationship poses a significant risk.
- Legal Contingencies: The company is involved in ongoing patent litigation with Alaris Medical Systems (appealing a $4.8M fee award), Medegen MMS (awaiting appeal decision on non-infringement), and RyMed Technologies. Management believes these will not have a material adverse effect, but outcomes are uncertain.
Investor Verification Checklist
- Auction Rate Securities Liquidity: Verify the current status of the $23.6 million in Level 3 auction rate securities and the company's ability to liquidate them without loss.
- Hospira Dependency: Assess the stability of the relationship with Hospira, which accounts for over two-thirds of revenue, and the impact of the MCDA pricing terms on critical care margins.
- Legal Exposure: Monitor the status of the appeal regarding the $4.8M legal fee judgment against Alaris and the outcome of the Medegen appeal.
- Margin Sustainability: Confirm if the 43% gross margin guidance can be maintained given rising raw material costs (estimated at $2.0M annually) and potential price erosion in critical care products.
- Capital Expenditures: Review the execution of the estimated $14.0 million in capital expenditures for 2008, particularly regarding the "ICU Production System" (IPS) efficiency initiatives.